...
首页> 外文期刊>Heart >Predictors of 1-year mortality in patients with aortic regurgitation after transcatheter aortic valve implantation: an analysis from the multicentre German TAVI registry
【24h】

Predictors of 1-year mortality in patients with aortic regurgitation after transcatheter aortic valve implantation: an analysis from the multicentre German TAVI registry

机译:经导管主动脉瓣植入术后主动脉瓣关闭不全患者1年死亡率的预测指标:来自德国多中心TAVI注册中心的分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objective Residual aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) has been associated with increased mortality. Nevertheless, a considerable proportion of these patients survives and appears to tolerate AR. Identification of patients at higher risk of death may assist in tailoring therapy, but predictors of mortality in this subset of patients is largely unknown. Methods A total of 1432 patients were included in the German TAVI registry. One-year follow-up data were available for 1318 patients (92%). Of the latter, 201 patients (15.2%) had more-than-mild AR as evaluated by angiography and represent the population of the current analysis. Among these patients, baseline demographic, clinical, echocardiographic and angiographic characteristics were compared among survivors and non-survivors to identify factors associated with mortality at 1 year. Results Mean age was 81.2±6.6 years and men represented 55%. The mean logistic EuroSCORE was 22±15%. Overall, 92% of patients received the Medtronic CoreValve and 8% received the Edwards Sapien valve. At 1 year, 61 patients (31%) with more-than-mild post-TAVI AR had died. Compared with patients who survived, patients who died had more commonly coronary artery disease, peripheral arterial disease and chronic renal impairment. Patients who died had a lower baseline LVEF (44+18% vs 52±16%, p=0.002), higher prevalence of more-than-mild (≥2+) mitral regurgitation (44% vs 27%, p=0.001), and a higher systolic pulmonary artery pressure (51±18 mm Hg vs 44±19 mm Hg, p=0.002), but the severity of aortic stenosis was similar, and the prevalence and severity of pre-TAVI AR was comparable (any AR in 88% vs 83%, respectively, p=0.29). Using Cox regression analysis, only baseline mitral regurgitation ≥2+ (HR 1.77, 95% CI 1.05 to 2.99, p=0.03) and systolic pulmonary artery pressure (HR 1.15, 95% CI 1.01 to 1.33, p=0.04) were independently associated with 1-year mortality, while female gender was protective (HR 0.54, 95% CI 0.30 to 0.96, p=0.03). Conclusions We identified preprocedural characteristic associated with 1-year mortality in patients with more-than-mild AR after TAVI. More-than-mild baseline mitral regurgitation, higher systolic pulmonary artery pressure and male gender were independently associated with worse outcome.
机译:目的经导管主动脉瓣植入术(TAVI)后主动脉瓣关闭不全(AR)与死亡率增加相关。尽管如此,这些患者中仍有相当一部分幸存下来,并且似乎可以耐受AR。识别较高死亡风险的患者可能有助于定制治疗,但是在这部分患者中死亡的预测因素很大程度上未知。方法德国TAVI登记处共纳入1432名患者。有1318例患者(92%)可获得一年的随访数据。在后者中,通过血管造影术评估的201例(15.2%)AR程度较轻,代表了当前分析的人群。在这些患者中,比较了幸存者和非幸存者的基线人口统计学,临床,超声心动图和血管造影特征,以确定与1年死亡率相关的因素。结果平均年龄为81.2±6.6岁,男性占55%。 Logistic EuroSCORE平均为22±15%。总体而言,有92%的患者接受了Medtronic CoreValve,有8%的患者接受了Edwards Sapien瓣膜。在1年时,有61例(31%)的TAVI AR后病情较轻者死亡。与存活的患者相比,死亡的患者更常见于冠状动脉疾病,外周动脉疾病和慢性肾功能不全。死亡患者的基线LVEF较低(44 + 18%vs 52±16%,p = 0.002),二尖瓣反流超过轻度(≥2+)的患病率较高(44%vs 27%,p = 0.001) ,并且收缩期肺动脉压较高(51±18 mm Hg vs 44±19 mm Hg,p = 0.002),但主动脉瓣狭窄的严重程度相似,TAVI前期AR的患病率和严重程度是可比的(任何AR分别为88%和83%,p = 0.29)。使用Cox回归分析,仅基线二尖瓣反流≥2+(HR 1.77,95%CI 1.05至2.99,p = 0.03)和收缩期肺动脉压(HR 1.15,95%CI 1.01至1.33,p = 0.04)独立相关死亡率为1年,而女性则具有保护性(HR 0.54,95%CI 0.30至0.96,p = 0.03)。结论我们确定了TAVI后轻度AR患者的1年死亡率相关的术前特征。基线二尖瓣反流多于轻度,收缩期肺动脉高压和男性性别均与不良预后相关。

著录项

  • 来源
    《Heart》 |2014年第16期|1250-1256|共7页
  • 作者单位

    Heart Center, Segeberger Kliniken GmbH, Academic Teaching Hospital of the Universities of Kiel & Hamburg, Am Kurpark 1, 23795 Bad Segeberg, Germany;

    Department of Cardiology, Heart Center Ludwigshafen, Ludwigshafen, Germany;

    Department of Cardiology, Gemeinschaftskrankenhaus, Bonn, Germany;

    Heart Center, University of Leipzig, Leipzig, Germany;

    Cardiovascular Center Frankfurt, Sankt Katharinen, Frankfurt am Main, Germany;

    Department of Cardiology, Asklepios Clinics Sankt Georg, Hamburg, Germany;

    Department of Cardiology, University of Essen, Essen, Germany;

    Department of Cardiology, Heart Center Bremen, Bremen, Germany;

    Department of Cardiology, Muenchen Schwabing Clinic, Munich, Germany;

    Department of Cardiology, Muenchen-Bogenhausen Clinic, Munich, Germany;

    Institute of Myocardial Infarction Research, Ludwigshafen, Germany;

    Institute of Myocardial Infarction Research, Ludwigshafen, Germany;

    Heart Center, Segeberger Kliniken GmbH, Bad Segeberg, Germany;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号